Literature DB >> 11158174

De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.

R B van der Luijt 1, P H van Zon , R P Jansen, C J van der Sijs-Bos , C C Wárlám-Rodenhuis, M G Ausems.   

Abstract

Germline mutations in either of the two major breast cancer predisposition genes, BRCA1 and BRCA2, account for a significant proportion of hereditary breast/ovarian cancer. Identification of breast cancer patients carrying mutations of these genes is primarily based on a positive family history of breast/ovarian cancer or early onset of the disease or both. In the course of mutation screening of the BRCA1 and BRCA2 genes in a hospital based series of patients with risk factors for hereditary breast/ovarian cancer, we identified a germline mutation in the BRCA2 gene (3034del4) in a patient with early onset breast cancer and no strong family history of the disease. Subsequent molecular analysis in her parents showed that neither of them carried the mutation. Paternity was confirmed using a set of highly polymorphic markers, showing that the proband carried a de novo germline mutation in the BRCA2 gene. Interestingly, 3034del4 is a recurrent mutation occurring in a putative mutation prone region of the BRCA2 gene. Our study presents the first case in which a de novo germline mutation in the BRCA2 gene has been identified, and supports previous results of haplotype studies, confirming that the 3034del4 mutation has multiple independent origins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158174      PMCID: PMC1734809          DOI: 10.1136/jmg.38.2.102

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

1.  De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation.

Authors:  A Tesoriero; C Andersen; M Southey; G Somers; M McKay; J Armes; M McCredie; G Giles; J L Hopper; D Venter
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

2.  Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

Authors:  S L Neuhausen; A K Godwin; R Gershoni-Baruch; E Schubert; J Garber; D Stoppa-Lyonnet; E Olah; B Csokay; O Serova; F Lalloo; A Osorio; M Stratton; K Offit; J Boyd; M A Caligo; R J Scott; A Schofield; E Teugels; M Schwab; L Cannon-Albright; T Bishop; D Easton; J Benitez; M C King; B A Ponder; B Weber; P Devilee; A Borg; S A Narod; D Goldgar
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

3.  Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group.

Authors:  S E Antonarakis
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

4.  1996 ASHG Presidential Address. Toward the 21st century.

Authors:  C J Epstein
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

5.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

6.  Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.

Authors:  E J Meijers-Heijboer; L C Verhoog; C T Brekelmans; C Seynaeve; M M Tilanus-Linthorst; A Wagner; L Dukel; P Devilee; A M van den Ouweland; A N van Geel; J G Klijn
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

7.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.

Authors:  S L Neuhausen; S Mazoyer; L Friedman; M Stratton; K Offit; A Caligo; G Tomlinson; L Cannon-Albright; T Bishop; D Kelsell; E Solomon; B Weber; F Couch; J Struewing; P Tonin; F Durocher; S Narod; M H Skolnick; G Lenoir; O Serova; B Ponder; D Stoppa-Lyonnet; D Easton; M C King; D E Goldgar
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

9.  Rapid detection of BRCA1 mutations by the protein truncation test.

Authors:  F B Hogervorst; R S Cornelis; M Bout; M van Vliet; J C Oosterwijk; R Olmer; B Bakker; J G Klijn; H F Vasen; H Meijers-Heijboer
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

10.  Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.

Authors:  M J Ligtenberg; F B Hogervorst; H W Willems; P J Arts; G Brink; S Hageman; E A Bosgoed; E Van der Looij; M A Rookus; P Devilee; E M Vos; G Wigbout; P M Struycken; F H Menko; E J Rutgers; E H Hoefsloot; E C Mariman; H G Brunner; L J Van 't Veer
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  10 in total
  12 in total

1.  Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer.

Authors:  Emma Edwards; Catharina Yearwood; Julie Sillibourne; Diana Baralle; Diana Eccles
Journal:  Fam Cancer       Date:  2009-07-21       Impact factor: 2.375

2.  Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.

Authors:  Safinaz S Ibrahim; Elsayed E Hafez; Mervat M Hashishe
Journal:  J Exp Clin Cancer Res       Date:  2010-06-25

3.  Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.

Authors:  L Golmard; C Delnatte; A Laugé; V Moncoutier; C Lefol; K Abidallah; H Tenreiro; F Copigny; M Giraudeau; C Guy; C Barbaroux; G Amorim; A Briaux; V Guibert; J Tarabeux; S Caputo; A Collet; P Gesta; O Ingster; M-H Stern; E Rouleau; A de Pauw; M Gauthier-Villars; B Buecher; S Bézieau; D Stoppa-Lyonnet; C Houdayer
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

4.  Routine TP53 testing for breast cancer under age 30: ready for prime time?

Authors:  Jeanna M McCuaig; Susan R Armel; Ana Novokmet; Ophira M Ginsburg; Rochelle Demsky; Steven A Narod; David Malkin
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

5.  A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.

Authors:  Ava Kwong; Enders K O Ng; Edmund Y H Tang; Chris L P Wong; Fian B F Law; Candy P H Leung; Aaron Chan; M T Cheung; M Y To; Edmond S K Ma; Dee W West; James M Ford
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

6.  A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.

Authors:  Zaida Garcia-Casado; Ignacio Romero; Antonio Fernandez-Serra; Luis Rubio; Francisco Llopis; Ana Garcia; Pilar Llombart; Jose A Lopez-Guerrero
Journal:  BMC Med Genet       Date:  2011-10-11       Impact factor: 2.103

7.  Novel de novo BRCA2 mutation in a patient with a family history of breast cancer.

Authors:  Thomas V O Hansen; Marie Luise Bisgaard; Lars Jønson; Anders Albrechtsen; Bettina Filtenborg-Barnkob; Hans Eiberg; Bent Ejlertsen; Finn C Nielsen
Journal:  BMC Med Genet       Date:  2008-07-02       Impact factor: 2.103

8.  BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.

Authors:  Fabrice Kwiatkowski; Marie Arbre; Yannick Bidet; Claire Laquet; Nancy Uhrhammer; Yves-Jean Bignon
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

9.  Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients.

Authors:  Ava Kwong; Enders K O Ng; Fian B F Law; H N Wong; Anna Wa; Chris L P Wong; Allison W Kurian; Dee W West; James M Ford; Edmond S K Ma
Journal:  Breast Cancer Res Treat       Date:  2012-10-26       Impact factor: 4.872

10.  The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.

Authors:  Julie Dutil; Volha A Golubeva; Alba L Pacheco-Torres; Hector J Diaz-Zabala; Jaime L Matta; Alvaro N Monteiro
Journal:  Breast Cancer Res Treat       Date:  2015-11-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.